Stem cells stir EC research funding debate:
This article was originally published in Clinica
The European Research Council has agreed to allow EU funds to be used for embryonic stem cell research, subject to the applicable legislation in the individual member states. The decision, already approved by the European Commission and the European Parliament (see Clinica No 986, p 4), was ratified at last week's meeting to approve the VI Research Framework Programme 2002-06. The ethical issues surrounding stem cell research remain a "particular focus of debate", according to the minutes of the meeting. Other issues included a proposed budget of E2.2 billion ($2.5 billion) for genomics and biotechnology, E1.15 billion for advanced genomics and its healthcare applications, and E1.05 billion to "tackle the principal diseases".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.